Head to head
Vylor Inc vs DRUGS MADE IN AMERICA ACQ II CORP
Side-by-side on the measures that matter, with a plain-English read. Full detail: VYLR · DMII
VYLR
Vylor Inc
73.15+0.49%
1-year price shape — not enough history yet
Quant Rating C · 0/100
vs
DMII
DRUGS MADE IN AMERICA ACQ II CORP
10.19+0.00%
1-year price shape — not enough history yet
Quant Rating C · 0/100
It’s close.
| VYLR | DMII | |
|---|---|---|
| Snapshot | ||
| Sector | Shell Companies | Shell Companies |
| Last price | 73.15 | 10.19 |
| Change today | +0.49% | +0.00% |
| 1-year return | -- | -- |
| Market cap | $48.81B | $649.10M |
| 52-week range | 65.00 – 75.49 | 9.86 – 10.33 |
| Valuation | ||
| P/E (TTM) | 103.17 | 34.90 |
| P/E percentile, own 5-yr range | 100th | 60th |
| P/B | 3.22 | 1.31 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 0.56 | 0.15 |
| Net profit (TTM) | $376.30M | $9.56M |
| Revenue (TTM) | -- | $0 |
| Revenue growth (YoY) | +12.4% | -- |
| Gross margin | 54.5% | -- |
| Operating margin | 18.7% | -- |
| Net margin | 4.5% | -- |
| Free cash flow (TTM) | -- | $-1.28M |
| Ownership & sentiment | ||
| Institutional ownership | 0.1% | 76.9% |
| Insider activity (12mo) | 37 buy / 12 sell | 6 buy / 2 sell |
| Short interest (% of float) | -- | 0.2% |
| Analyst consensus | 100% buy (3) | -- |
| Analyst price target | $79 (+8%) | -- |
| StockVane view | ||
| StockVane Quant Rating | C (0) | C (0) |
| Company | ||
| Employees | -- | 2 |
| Founded | -- | -- |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.